Intelligencia

Gain access to expertly curated and harmonized data for modeling, data science applications, and business intelligence in the biomedical field.

Intelligencia AI offers a patented SaaS platform, Portfolio Optimizer and Dynamic Benchmarks, for AI-driven probability-of-success assessments for drug development programs.

Intelligencia AI’s suite of solutions assesses drug success probability and provides clinical development insights.

The company seeks individuals across disciplines including data science, bioinformatics, and software engineering.

Dimitris is a Corporate Advisor who guides the organization on digital transformation, artificial intelligence, data strategy, and innovation in drug development. He has more than 30 years of experience and is a Director at Arsenal Capital Partners.

Gerry is a Scientific Advisor to Intelligencia with experience in AI, markets, and institutional design. Spyros is a Professor of Artificial Intelligence at the University of Oxford and Research Co-Director of the AI & Society Lab at the Oxford-UBS Centre for Applied AI.

Heracles oversees Intelligencia AI’s software architecture, including cloud infrastructure, data extraction pipelines, its SaaS platform, analytics and reporting toolchains, and APIs for programmatic data consumption. He previously worked for more than 12 years as a software engineer.

Jeremy is a Corporate Advisor to Intelligencia and has nearly three decades of experience in healthcare, technology, data, and strategy. His work includes high-growth healthcare companies and institutional investors.

Intelligencia AI applies data-driven AI to drug development and presents its mission, leadership team, and core values.

Intelligencia AI offers AI for clinical development and business decisions.

Intelligencia AI’s solutions provide AI-driven insights for drug development, support portfolio strategy, reduce risks, and predict success.